Atrium's Repayment Storm Clears: Stage 3 Drawdown Signals a Portfolio Inflection

Atrium MIC reported a second quarter that looks, on the surface, like a tale of two forces: an unusually high wave of repayments that shrank the mortgage book, and a simultaneous, decisive improvement in credit quality. The headline numbers are straightforward. The portfolio fell to $860.1M, down 6.2% from year-end, as “$88.2 million of mortgage principal advanced and $121.9 million repaid and transferred net of write-offs of $1 million” — Chris Anastasopoulos, Chief Financial Officer · 2026-08-06 created a portfolio turnover rate of 58% on an annualized basis, versus 38% in 2025. That is a lot of churn. But buried in that churn is the real story: the resolutions that were telegraphed on prior calls actually happened.

The two large Stage 3 loans, representing $41 million, were resolved during the quarter — one via sale, one via a new joint venture partner — exactly as management had guided. As a result, “Stage 3 loans, which are considered impaired loans, decreased from $95 million last quarter to $62 million at the end of Q2” — Robert G. Goodall, Chief Executive Officer · 2026-08-06. That is a 28% quarter-over-quarter drop and a direct hit to credit risk. The total allowance for credit losses stayed roughly flat at $30.1M, but as a percentage of the now-smaller portfolio it rose to 350 basis points, up from 347 bps. The reassuring part is that the Stage 3 loan drawdown was driven by repayment, not write-downs. Borrowers remained current on interest even as they were classified as impaired, a reminder of the current IFRS 9 quirk that forces a more conservative staging than the underlying cash flows might suggest.

The Repayment activity was the dominant theme on the call, but it is being cast as a temporary phenomenon. Management's confidence rests not just on the resolution of the two large Stage 3 loans, but on a visible pipeline. The loan production engine appears to have re-accelerated — Rob Goodall noted it was the "highest level of loan production since Q2 of 2025" — and the book is being deliberately rotated toward what the company views as its two preferred sectors: commercial and single-family. Combined, those now represent 53.4% of the portfolio, up from 49% a quarter earlier and just 23% in 2023. This is a structural shift, not a tactical one, and it is showing up in the credit metrics.

The most revealing commentary came from the Q&A, where management explained why Stage 2 loans were up even though credit fundamentals were stable. Roughly $24M of mortgages migrated to Stage 2 solely for being over 30 days past their contractual maturity, a classification that would not have existed under the old accounting rules.

So it's just a fact of life in commercial real estate lending that sometimes borrowers ... don't sign back a renewal offer, and they search to see if they can find cheaper financing.

Underneath all of this is a broader structural theme: the Canadian real estate market is slowly healing. The GTA saw resales up 9.4% year-over-year, new home sales were up 102% in the first half, and low-rise sales were actually 36% above the 10-year average. The weakness remains concentrated in high-rise condos, where inventory under construction has dropped to 38,250 units from a peak of 105,400 in mid-2023. “It's still early in the quarter. I think we'll certainly be higher than we ended this quarter at” — Robert G. Goodall, Chief Executive Officer · 2026-08-06 — a direct reference to the goal of pushing the portfolio back above $900M by year-end. The company is also now drawing on a new Alberta office that has already originated three distinct loan types — a purpose-built rental, a small-bay industrial, and a medical office conversion — expanding its geographic reach beyond Ontario and BC.

This report reads as a bridge quarter: the messy repayment spike is giving way to a cleaner, faster-growing book. The prior two calls were all about managing the Stage 3 herd — the February call explicitly promised the $31M loan would be a "full recovery," and the November call flagged the irony that resolving problem loans actually drags down the average yield. Both themes have now played out. The medical office loan in Alberta is a fresh, company-specific development that adds a new vertical to the lending mix. It is a small step, but it signals that the origination team is not just defending the book; it is expanding it.

If the $900M target is the near-term goal, the more important long-term signal is the intentional reshaping of the portfolio toward lower-risk, income-producing assets. That shift has been occurring for three years, but Q2 2026 accelerated it. With Stage 3 loans now down to roughly 7% of the portfolio and the allowance buffer still above 3.4%, the credit story is improving at the same time the market is stabilizing. Atrium appears to be on the front end of a reconstruction — and for a name that has been through a multi-year downturn, that is an inflection worth watching.